ABVC - ABVC BioPharma Vitargus phase 2 protocol study cleared by Thai hospital ethics committee

• ABVC BioPharma ( NASDAQ: ABVC ) on Thursday said it had got an approval from the ethics committee of a Thai hospital to conduct a phase 2 clinical study protocol for its vitreous substitute Vitargus.
• Shares of the micro-cap clinical-stage biopharmaceutical company opened 5.6% higher at $0.78.
• The approval from the ethics committee of the Ramathibodi Hospital, Mahidol University follows a similar nod in July from the Srinagarind Hospital, Khon Kaen University, ABVC said in a statement .
• ABVC's Vitargus is a substitute for the vitreous humor in the eye, which is the gel-like fluid that fills the eye cavity.
• The two hospitals now expect to get a Thai FDA investigational product import license within the next 30 days, which will allow them to initiate the clinical study in the country, ABVC said.
• "Animal studies requested by the United States FDA in connection with Vitargus are going well, making it likely that Phase II studies can be conducted in the US starting in 2024," said ABVC CEO Howard Doong.

For further details see: